Andere Sprachen EuBiologics Co., Ltd.

Aktien

A206650

KR7206650004

A206650

Schlusskurs Korea S.E. Andere Börsenplätze 00:00:00 01.07.2024			% 5 Tage	% 1. Jan.
12’070 ^KRW	+0.58%		-1.07%	+5.23%

29.01.	Simbabwe startet Cholera-Impfkampagne von Haus zu Haus	RE
2023	Der Impfstoff Eucorvac-19 von Pop Biotechnologies und Eubiologics erreicht das Ziel in der Phase-3-Studie	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

EuBiologics co.,Ltd - SNAP Platform enters Phase I clinical studies for RSV	13.05.
Gavi and UNICEF welcome approval of new oral cholera vaccine	19.04.
Gavi and Unicef Welcome Approval of New Oral Cholera Vaccine [press release]	19.04.
What's Behind the Worldwide Shortage of Cholera Vaccines? for Starters, They're Only Made By One Company [analysis]	13.03.
Reservas de vacunas contra el cólera, "vacías" ante aumento de casos	14.02.
Zimbabwe launches door-to-door cholera vaccination campaign	29.01.
Pop Biotechnologies and Eubiologics' Eucorvac-19 Vaccine Hits Target in Phase 3 Trial	14.07.23
Gavi - Global vaccine alliance outlines path to sustainable cholera vaccine supply	23.05.23
EuBiologics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	21.03.23
POP Biotechnologies' SNAP Vaccine System Safe and Effective in a Phase II Clinical Trial for COVID-19	01.12.22
POP Biotechnologies' next-gen vaccine technology to enter COVID-19 phase III clinical trials	07.02.22
Eubiologics Co., Ltd. Announces Phase Iii Clinical Trial Ind Approval of Eucorvac-19, Covid-19 Vaccine Candidate, in South Korea	03.02.22
Clips Co., Ltd. announced that it expects to receive KRW 2.50003 billion in funding from EuBiologics Co., Ltd., SK bioscience Co.,Ltd., BNC Korea Co., Ltd.	27.01.22
SK bioscience : S.Korea to begin producing Novavax COVID-19 vaccine as early as June	12.04.21
EuBiologics Gets an IND Approval for Phase I/II Clinical Trial of 'EuCorVac-19' in Korea	21.01.21
EuBiologics Co., Ltd.(KOSDAQ:A206650) added to S&P Global BMI Index	23.09.19
ATGC Co., Ltd. announced that it has received KRW 2.1 billion in funding from EuBiologics Co., Ltd.	10.01.19
ATGC Co., Ltd. announced that it expects to receive KRW 2.1 billion in funding from EuBiologics Co., Ltd.	04.01.19
EuBiologics Co., Ltd. announced that it has received KRW 30.00000351 billion in funding	30.04.18
EuBiologics Co., Ltd. announced that it expects to receive KRW 30 billion in funding	12.02.18

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen EuBiologics Co., Ltd.

Aktien

A206650

KR7206650004

A206650

Andere Sprachen

Filter